INTI · Inhibitor Therapeutics, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“These conditions and events raise substantial doubt about the Company's ability to continue as a going concern. ... Because management's plans have not yet been fully executed and are not within the Company's control, the implementation of such plans cannot be considered probable. As a result, the Company has concluded that management's plans do not currently alleviate substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | — | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| — | — | — | — | — | -$14.84K | $1058 | $14.54K | $14.03K | $17.87K | $21.99K | — | — | — | — | |
| $1.7M | $1.7M | $1.76M | $1.38M | $6150 | $4905 | $185.29K | $1.21M | $2.63M | $2.23M | $2.64M | $1.68M | $2.43M | $1.07M | — | |
| $1.67M | $1.73M | $1.9M | $2.02M | $651.78K | $320.49K | $873.7K | $1.54M | $1.93M | $2.89M | $4.38M | $2.27M | $1.51M | $817.32K | $560.67K | |
| $3.37M | $3.43M | $3.66M | $3.4M | $657.93K | $325.4K | $1.06M | $2.75M | $4.56M | $5.12M | $7.02M | $3.95M | $3.94M | $2M | $560.67K | |
| -$3.37M | -$3.43M | -$3.66M | -$3.4M | -$657.93K | -$325.4K | -$1.06M | -$2.75M | -$4.56M | -$5.12M | -$7.02M | -$3.95M | -$3.94M | -$2M | -$560.67K | |
| — | — | — | — | $23.23K | $14.84K | — | — | — | — | — | — | $37.48K | $1923 | — | |
| — | — | — | -$3.03M | $12.16M | -$298.63K | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | $55.11K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| -$3.31M | -$3.3M | -$3.34M | -$3.03M | $12.11M | -$298.63K | -$1.06M | -$2.73M | -$4.55M | -$5.1M | -$7M | -$3.95M | -$3.98M | -$1.84M | $186.37K | |
| — | — | — | -$3.03M | $11.92M | -$498.63K | — | — | — | — | — | — | — | — | — | |
| USD/shares | -$0.02 | -$0.02 | -$0.02 | -$0.02 | $0.03 | $0.00 | — | — | — | — | — | — | — | -$0.10 | $0.01 |
| USD/shares | -$0.02 | -$0.02 | -$0.02 | -$0.02 | $0.03 | $0.00 | — | — | — | — | — | — | — | -$0.10 | $0.01 |
| shares | — | 172.51M | 172.26M | 171.95M | 366.18M | 376.25M | 371.93M | 370.43M | 369.81M | 366.62M | 288.75M | 232.62M | 95.88M | 17.94M | 13.65M |
| shares | — | 172.51M | 172.26M | 171.95M | 366.18M | 376.25M | 371.93M | 370.43M | 369.81M | 366.62M | 288.75M | 232.62M | 95.88M | 17.94M | 13.65M |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2019–FY2020: $99.18K in dividends.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current long-term debt and lease obligations | 2026-06-30 | USD 26,262 | 10-Q filed 2026-08-14 |
| Noncurrent long-term debt and lease obligations | 2026-06-30 | USD 21,566 | 10-Q filed 2026-08-14 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 268 similar-size Biotechnology companies (of 559 listed).